John C. VanRens | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where John C. VanRens is active.

Explore More

Publication

Featured researches published by John C. VanRens.

Bioorganic & Medicinal Chemistry Letters | 2003

The development of new triazole based inhibitors of tumor necrosis factor-α (TNF-α) production

Steven K. Laughlin; Michael Philip Clark; Jane Far-Jine Djung; Adam Golebiowski; Todd A. Brugel; Mark Sabat; Roger G. Bookland; Matthew J. Laufersweiler; John C. VanRens; Jennifer A. Townes; Biswanath De; Lily C. Hsieh; Susan C. Xu; Richard Walter; Marlene Mekel; Michael J. Janusz

4-Aryl-3-pyridyl and 4-aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel isoxazolone five-membered heterocyclic core are described. Many showed sub-micromolar activity against lipopolysaccharide-induced TNF-alpha production.

Bioorganic & Medicinal Chemistry Letters | 2001

The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.

Joshua Spector Tullis; Matthew J. Laufersweiler; John C. VanRens; Michael George Natchus; Roger G. Bookland; Neil Gregory Almstead; Stanislaw Pikul; Biswanath De; Lily C. Hsieh; Michael J. Janusz; Todd M. Branch; Sean X. Peng; Yingkun Y. Jin; Tomas Hudlicky; Kofi Oppong

A series of carboxylic acids was prepared based on cyclohexylglycine scaffolds and tested for potency as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for five enzymes within the MMP family, and a number of inhibitors such as compound 18 display low nanomolar potency for MMP-2 and MMP-13, while selectively sparing MMP-1 and MMP-7.

Journal of Medicinal Chemistry | 2004

Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production

Michael Philip Clark; Steven K. Laughlin; Matthew J. Laufersweiler; Roger G. Bookland; Todd A. Brugel; Adam Golebiowski; Mark Sabat; Jennifer A. Townes; John C. VanRens; Jane Far-Jine Djung; Michael G. Natchus; Biswanath De; Lily C. Hsieh; Susan C. Xu; Rick L. Walter; Marlene Mekel; S.A. Heitmeyer; Kimberly K. Brown; Karen Juergens; Yetunde Olabisi Taiwo; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2007

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Michael Philip Clark; Kelly M. George; Roger G. Bookland; Steven K. Laughlin; Kumar D. Thakur; Wenlin Lee; Jan Richard Davis; Ed J. Cabrera; Todd A. Brugel; John C. VanRens; Matthew J. Laufersweiler; Jennifer A. Maier; Mark Sabat; Adam Golebiowski; Vijay Easwaran; Mark E. Webster; Biswanath De; George Zhang

Bioorganic & Medicinal Chemistry Letters | 2006

The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck)

Mark Sabat; John C. VanRens; Matthew J. Laufersweiler; Todd A. Brugel; Jennifer A. Maier; Adam Golebiowski; Biswanath De; Vijayasurian Easwaran; Lily C. Hsieh; Richard Walter; Marlene Mekel; Artem G. Evdokimov; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2006

Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1

Todd A. Brugel; Jennifer A. Maier; Michael Philip Clark; Mark Sabat; Adam Golebiowski; Roger G. Bookland; Matthew J. Laufersweiler; Steven K. Laughlin; John C. VanRens; Biswanath De; Lily C. Hsieh; Marlene Mekel; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2004

The development of new bicyclic pyrazole-based cytokine synthesis inhibitors

Jennifer A. Townes; Adam Golebiowski; Michael Philip Clark; Matthew J. Laufersweiler; Todd A. Brugel; Mark Sabat; Roger G. Bookland; Steve K. Laughlin; John C. VanRens; Biswanath De; Lily C. Hsieh; Susan C. Xu; Michael J. Janusz; Richard Walter

Bioorganic & Medicinal Chemistry Letters | 2006

Development of N-4,6-pyrimidine-N-alkyl-N′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase

Jennifer A. Maier; Todd A. Brugel; Mark Sabat; Adam Golebiowski; Matthew J. Laufersweiler; John C. VanRens; Corey R. Hopkins; Biswanath De; Lily C. Hsieh; Kimberly K. Brown; Vijayasurian Easwaran; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2005

The development of monocyclic pyrazolone based cytokine synthesis inhibitors

Adam Golebiowski; Jennifer A. Townes; Matthew J. Laufersweiler; Todd A. Brugel; Michael Philip Clark; Cynthia Monesa Clark; Jane Far-Jine Djung; Steven K. Laughlin; Mark Sabat; Roger G. Bookland; John C. VanRens; Biswanath De; Lily C. Hsieh; Michael J. Janusz; Richard Walter; Mark E. Webster; Marlene Mekel

Bioorganic & Medicinal Chemistry Letters | 2004

The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted [5,5]-bicyclic pyrazolones

Matthew J. Laufersweiler; Todd A. Brugel; Michael Philip Clark; Adam Golebiowski; Roger G. Bookland; Steven K. Laughlin; Mark Sabat; Jennifer A. Townes; John C. VanRens; Biswanath De; Lily C. Hsieh; S.A. Heitmeyer; Karen Juergens; Kimberly K. Brown; Marlene Mekel; Richard Walter; Michael J. Janusz

Explore More